危重症合并急性肾损伤患者尿Klotho水平更低且与主要不良肾脏事件相关
这项单中心前瞻性病例对照研究纳入ICU中54例KDIGO标准AKI≥2期患者与52例按年龄、性别、基线eGFR匹配的无AKI对照,在AKI诊断或ICU入住后24-48小时留取配对血尿标本。主要终点为90天主要不良肾脏事件(MAKE-90,包括全因死亡、依赖肾脏替代治疗或eGFR较基线下降≥50%),41.5%患者发生MAKE-90。AKI患者尿Klotho/肌酐比值更低、血清完整FGF23更高;校正模型中尿Klotho/Cr最高三分位与MAKE-90风险降低95%独立相关(AKI患者中降低81%),血清完整FGF23最高三分位与MAKE-90风险升高超过300%相关。作者认为这些生物标志物有潜力用于构建ICU肾脏结局风险预测模型。
要点
- ICU中AKI≥2期患者尿Klotho/肌酐比值显著低于年龄、性别、基线eGFR匹配的无AKI对照,血清完整FGF23则更高。
- 90天MAKE-90(全因死亡、依赖肾脏替代治疗或eGFR较基线下降≥50%)发生率为41.5%(44例)。
- 校正模型中尿Klotho/Cr最高三分位与最低三分位相比,MAKE-90总体风险降低95%,AKI患者中降低81%。
- 血清完整FGF23最高三分位与最低三分位相比,MAKE-90风险升高超过300%。
- 作者认为尿Klotho/Cr与完整FGF23有潜力单独或联合用于ICU肾脏结局的新型风险预测模型。
适用人群与场景
- ICU收治的成人患者,包括KDIGO标准AKI≥2期患者54例和无AKI对照52例;对照按年龄、性别、基线eGFR匹配。
诊断标准与关键阈值
- AKI采用KDIGO标准定义,仅纳入AKI≥2期患者。
- MAKE-90为复合终点:全因死亡、依赖肾脏替代治疗或eGFR较基线下降≥50%。
研究设计与关键结果
- 单中心、前瞻性、病例对照研究,纳入ICU中54例AKI≥2期患者与52例无AKI对照,在AKI诊断或ICU入住后24-48小时留取配对血清和尿液标本。
- 44例(41.5%)发生MAKE-90;发生MAKE-90者合并症更多、疾病严重度评分更高、AKI更普遍。
- AKI患者尿Klotho/肌酐比值低于ICU对照,血清完整FGF23水平高于ICU对照。
- 校正模型中尿Klotho/Cr最高三分位与最低三分位相比,MAKE-90总体风险降低95%,AKI患者中降低81%。
- 校正模型中血清完整FGF23最高三分位与最低三分位相比,MAKE-90风险升高超过300%。
证据类型、等级与局限
- 证据类型:单中心、前瞻性、病例对照研究。
- 作者认为这些生物标志物有潜力单独或联合用于ICU肾脏结局的新型风险预测模型。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为尿Klotho/Cr与血清完整FGF23有潜力单独或联合作为ICU肾脏结局新型风险预测模型的组成部分。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: Klotho and Fibroblast Growth Factor (FGF)-23 were recently postulated as candidate biomarkers and/or therapeutic targets in acute kidney injury (AKI). We examined whether urine Klotho and serum intact FGF23 levels were differentially and independently associated with major adverse kidney events (MAKE) in critically ill patients with and without AKI.
DESIGN: Single-center, prospective, case-control study.
SETTING: ICU in a tertiary medical center.
PATIENTS: 54 AKI patients and 52 controls without AKI admitted to the ICU.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: AKI was defined by KDIGO criteria and included only AKI stage ≥2. Controls were matched by age, gender, and baseline eGFR. Paired serum and urine samples were obtained 24-48h after AKI diagnosis (cases) or ICU admission (controls). The primary outcome was 90-day MAKE, which was the composite of all-cause death, dependence on renal replacement therapy or a 50% or higher decrease in eGFR from baseline. Forty-four (41.5%) patients developed MAKE-90. Patients who developed MAKE-90 had more comorbidity, higher acuity of illness scores and more prevalent AKI. Levels of urine Klotho adjusted by creatinine (Cr) were lower and serum intact FGF23 levels were higher in AKI patients vs. ICU controls. In adjusted models, the highest vs. lowest tertile of urine Klotho/Cr was independently associated with an overall 95% lower risk of MAKE-90 (81% lower risk in patients with AKI). The highest vs. lowest tertile of serum intact FGF23 was associated with >300% higher risk of MAKE-90.
CONCLUSIONS: Urine Klotho/Cr levels were significantly lower and serum intact FGF23 levels significantly higher in critically ill patients with AKI vs. matched-controls without AKI. When measured in the first 48h of ICU admission or AKI diagnosis, urine Klotho/Cr independently associated with major adverse kidney events, particularly in patients with AKI. These results show promise for testing these biomarkers -individually or in combination- as part of novel risk-prediction models of renal outcomes in the ICU.
参考来源
- Neyra JA, Li X, Mescia F, et al. Urine Klotho Is Lower in Critically Ill Patients With Versus Without Acute Kidney Injury and Associates With Major Adverse Kidney Events. Crit Care Explor. 2019. PMID: 32123869. doi:10.1097/cce.0000000000000016
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。